Literature DB >> 4701708

Gram-negative bacterial endocarditis in narcotic addicts.

J E Rosenblatt, J G Dahlgren, R S Fishbach, F P Tally.   

Abstract

The number of cases of bacterial endocarditis in drug addicts seen at UCLA and Wadsworth Veterans Administration hospitals increased sharply in 1971 over the average of the four preceding years. Enteric Gram-negative bacilli were the infecting organism in three of the seven cases seen in 1971 but were not found in any cases of endocarditis in the 1967-70 period. Medical treatment of the patients was, in general, unsuccessful in spite of the intensive use of newer antimicrobials active against enteric Gram-negative bacilli. One patient died with fulminant Pseudomonas endocarditis and two others (Pseudomonas and Serratia endocarditis) eventually required operations on the heart before a cure was achieved.

Entities:  

Mesh:

Year:  1973        PMID: 4701708      PMCID: PMC1455181     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  22 in total

1.  Serratia marcescens endocarditis. A report of a case involving Cross-Jones mitral valve prosthesis, with a review of the literature.

Authors:  R K Suri; D A Selby; G H Hawks; C B Baker
Journal:  Can Med Assoc J       Date:  1971-06-05       Impact factor: 8.262

2.  Sulphamethoxazole-trimethoprim: the first two years.

Authors:  D S Reeves
Journal:  J Clin Pathol       Date:  1971-07       Impact factor: 3.411

3.  Therapy of infections with the combination of carbenicillin and gentamicin.

Authors:  V Rodriguez; J P Whitecar; G P Bodey
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1969

Review 4.  The major medical complications of heroin addiction.

Authors:  D B Louria; T Hensle; J Rose
Journal:  Ann Intern Med       Date:  1967-07       Impact factor: 25.391

5.  Infective endocarditis at the Presbyterian Hospital in New York City from 1938-1967.

Authors:  C E Cherubin; H C Neu
Journal:  Am J Med       Date:  1971-07       Impact factor: 4.965

6.  The faucet aerator - a source of pseudomonas infection.

Authors:  D F Cross; A Benchimol; E G Dimond
Journal:  N Engl J Med       Date:  1966-06-23       Impact factor: 91.245

7.  Evaluation of the in vitro activity of tobramycin as compared with that of gentamicin sulfate.

Authors:  W H Traub; E A Raymond
Journal:  Appl Microbiol       Date:  1972-01

8.  Potentiation of inhibitory activity of colistin on Pseudomonas aeruginosa by sulphamethoxazole and sulphamethizole.

Authors:  N A Simmons
Journal:  Br Med J       Date:  1969-09-20

9.  SYNERGISM BETWEEN SULPHONAMIDE DRUGS AND ANTIBIOTICS OF THE POLYMYXIN GROUP AGAINST PROTEUS SP. IN VITRO.

Authors:  F E RUSSELL
Journal:  J Clin Pathol       Date:  1963-07       Impact factor: 3.411

10.  In vitro effects of carbenicillin combined with gentamicin or polymyxin B against Pseudomonas aeruginosa.

Authors:  T C Eickhoff
Journal:  Appl Microbiol       Date:  1969-09
View more
  5 in total

1.  Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli.

Authors:  J E Rosenblatt; P R Stewart
Journal:  Antimicrob Agents Chemother       Date:  1974-07       Impact factor: 5.191

2.  Two-stage replacement of tricuspid valve in active endocarditis.

Authors:  P Arneborn; V O Björk; L Rodriguez; M Svanbom
Journal:  Br Heart J       Date:  1977-11

3.  Blood-borne pulmonary infection with Nocardia asteroides in a heroin addict.

Authors:  M Vanderstigel; R Leclercq; C Brun-Buisson; A Schaeffer; J Duval
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

4.  Serratia Marcescens, a Rare and Devastating Cause of Endocarditis: A Case Report and Review of the Literature.

Authors:  Kelly Luttmann; Victoria R Starnes; Michael Haddad; Joan Duggan
Journal:  Cureus       Date:  2022-06-01

5.  Epidemiology and outcomes of non-HACEK infective endocarditis in the southeast United States.

Authors:  Michael P Veve; Eric D McCurry; Grace E Cooksey; Mahmoud A Shorman
Journal:  PLoS One       Date:  2020-03-10       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.